Back to mobile site

Mizuhoon Harmony Biosciences (HRMY): 'we recommend being opportunistic on yesterday's share weakness'

October 23, 2026 7:11 AM EDT Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $51.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY)The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login